



Antitumor Compounds from Marine Invertebrates

Guest Editor:

Dr. Cécile Debitus

IRD, Univ Brest, CNRS, Ifremer,
LEMAR, F-29280 Plouzane, France

Deadline for manuscript
submissions:

closed (23 December 2019)

Message from the Guest Editor

Since the discovery of the cytarabine derived from the spongothymidine isolated from the sponge *Cryptotethya crypta* in the 1950s, marine invertebrates have been an amazing source of innovative molecules, particularly in the field of anti-cancer drugs. Developed in the very first place to act for the survival of organisms in their environment, and refined by the evolution and adaptation needs of these often sessile and soft animals, these compounds are of unequalled originality. These molecules have most often been detected by screening on cellular targets, but the fine analysis of complex extracts leads to the isolation and identification of active principles, but also often to the isolation of analogues allowing better understanding of the mode of action of molecules and of the structural patterns essential to their activity.

We invite you to submit manuscripts for this Special Issue for reviews and original research articles describing novel naturally-occurring molecules and their close derivatives of anticancer interest, their cellular target, mode of action and structure-activity relationships, and their in vivo activities where appropriate.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Bill J. Baker

Department of Chemistry,
University of South Florida, 4202
E. Fowler Ave., CHE 205, Tampa,
FL 33620-5250, USA

Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [MEDLINE](#), [PMC](#), [Embase](#), [PubAg](#), [MarinLit](#), [AGRIS](#), and [other databases](#).

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmacology, Toxicology and Pharmaceutics (miscellaneous))

Contact Us

Marine Drugs Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/marinedrugs
marinedrugs@mdpi.com
[X@Marine_Drugs](#)